“It’s a word calculator on steroids.” — Daniel Chow, MD, MBA, of the University of California Irvine, on large language models like ChatGPT being used to plagiarize scientific research.
“It’s like gold. This is the reality. It’s crazy.” — Jody Dushay, MD, of Beth Israel Deaconess Medical Center in Boston, on diabetes patients’ difficulty getting their hands on semaglutide (Ozempic, Wegovy) and other GLP-1 receptor agonists amid shortages and sky-high demand.
“There is no rationale to believe that men are better surgeons than women.” — Loïc Sentilhes, MD, PhD, of Bordeaux University Hospital, on similar patient outcomes with a male or female surgeon performing cesarean sections.
“The first thing we did was to make a sincere apology and acknowledge that people were hurt by what was said.” — Thomas MacGillivray, MD, new president of the Society of Thoracic Surgeons, discussing the controversial comments made by outgoing president, John Calhoon, MD, during his address at the organization’s annual meeting.
“If patients are not getting what they need, it’s a problem.” — Somnath Bose, MD, MPH, of Beth Israel Deaconess Medical Center in Boston, on how non-drug medical needs are oft ignored in the early days following an ICU stay.
“There is no one around to say ‘No, you can’t have that. It doesn’t fit in your diet.'” — Perseus Patel, MD, of the University of California San Francisco, on the difficulty of getting patients with celiac and inflammatory bowel disease to stick to a gluten-free diet.
“We really like to have guardrails up and structure around that to make sure our kids get good care.” — Cora Breuner, MD, MPH, of the University of Washington and Seattle Children’s Hospital, on the unique needs of hospitalized adolescents.
“General internal medicine physicians are frontline doctors who diagnose, treat, and refer, when necessary, adults with [major depressive disorder] for additional collaborative mental health care.” — chair of the American College of Physicians’s clinical guidelines committee Timothy Wilt, MD, MPH, discussing the organization’s updated recommendations on starting treatment for patients in the acute phase of moderate-to-severe depression.
“The modest immunocompromise of a diabetic compared to the tremendous immunocompromise of someone who has received CD20-depleting therapies is a real spectrum here that we’re dealing with.” — Peter Marks, MD, PhD, of the FDA, discussing the challenge of making uniform dosing recommendations during an advisory committee on the future of COVID-19 vaccines.